



Expert UK-based CRO offering customised bioassay development, pharmacological profiling and compound screening

We have always valued our relationship with you and would like to stay connected. Under the new **General Data Protection Regulation (GDPR)**, it is mandatory for us to ask you to 'opt in' to continue receiving our emails. Please do so by clicking on the 'Yes' button below.

YES

You can unsubscribe from our emails at any point if you wish to stop hearing from us. We would like you to know that your personal information is safe with us and we do not share it with anyone.

Welcome to the latest edition of our newsletter

As innovations in drug discovery continue to abound, Aurelia Bioscience is working hard to support its clients and collaborators in their research. Our enthusiastic scientists have also been busy presenting at various prestigious events in the past few months, and there is more to follow!

Gary Allenby, Chief Scientific Officer, Aurelia Bioscience to give a talk at the Promega Discover Glo Tour 2018



Gary will be talking about Promega Target Engagement assay to assess residency time, selectivity and specificity for kinases using a novel high throughput scaffold-based format.

Residency times are an important pharmacological consideration to be developed alongside potency and permeability. Recently, Promega has developed a technology to examine residency time and specificity of compounds for selective kinases within a cellular background. The presentation will examine the combination of an ultra-high sensitive binding with NanoBRET and a novel scaffold technology to improve the work flows for non-equilibrium analysis of drug residence time, while maintaining data quality and consistency in a high throughput format. *To learn more, catch Gary on 23rd April in Alderley Park or 24th April in Cambridge.*

Dr. Gary Allenby



You can also meet us at the following conference in May:

Kinase 2018: towards new frontiers - 8th RSC / SCI symposium on kinase inhibitor design
Cambridge • May 14-15

A warm welcome!

Payash Bahuguna- Marketing Manager



Aurelia Bioscience has appointed Payash Bahuguna as the Marketing Manager to strengthen business development and marketing activities of our company. She will be attending a number of conferences in the forthcoming months including the Promega Discovery Glo Tour and the 8th Kinase RSC meeting. She will be working closely as a part of the Aurelia team to increase the connections with existing and prospective new clients along with improving the social media presence of the company.

Gary Allenby, Founder and Chief Scientific Officer of Aurelia Bioscience said “It is great to have Payash on the team. Payash will bring her marketing experience and talents together with her enthusiasm and fresh ideas to help Aurelia build and expand our successful collaborations with

clients”.

Payash has a Master’s degree in Biotechnology and Entrepreneurship from the University of Nottingham, as well as experience working with life science SMEs. “I am delighted to be a part of such a wonderful and experienced team. As the company is growing at such a rapid pace, I do look forward to some exciting times ahead!”, said Payash, on starting her new role.



Have you downloaded our eBook yet?

Read about some exciting bioassay technologies and learn how to combat common obstacles during bioassay development. Stay up-to-date with the current pace of innovation in drug discovery and ensure your research makes the biggest impact!

Contact Information:

Aurelia Bioscience
BioCity Nottingham,
Pennyfoot Street
Nottingham NG1 1GF
United Kingdom

Phone: +44 (0)115 837 0503

Email: info@aureliabio.com

Web: www.aureliabio.com